Lomitapide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Using the Evidence Pack provided, I selected the predicted indication with actual supporting evidence (rank 9, “hyperlipoproteinemia” — L1/S3/Proceed with Guardrails) rather than the TxGNN score-ranked #1 entry, because the evidence pack’s own repurposing_rationale flags ranks 1–8 and 10 (all rare platelet/thrombocytopenia disorders) as likely model embedding artifacts — each has a 99%+ TxGNN score but zero clinical trials and zero literature, and several rationale fields explicitly state this pattern indicates KG-embedding clustering noise rather than a real signal. Rank 9 is the only candidate with substantive evidence (12 trials, 19 publications), so it is the only one that can actually be evaluated. This substitution is noted below for transparency.
Lomitapide: From an Undocumented Original Indication to Hyperlipoproteinemia
One-Sentence Summary
Lomitapide’s original indication could not be extracted from this Evidence Pack (no Canadian license records, no structured original-indication data), though the collected literature consistently describes it as a microsomal triglyceride transfer protein (MTP) inhibitor already used for Homozygous Familial Hypercholesterolemia (HoFH). The TxGNN model — and independently, the collected real-world evidence — converge on Hyperlipoproteinemia as the most substantiated indication, supported by 12 clinical trials and 19 publications. Note: nine of the ten TxGNN-predicted indications in this pack (all rare platelet/thrombocytopenia disorders) returned zero trials and zero literature and are flagged in the source data itself as likely model artifacts — they are not covered further in this report.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no Canadian license records exist for this drug; the collected literature indicates it is used elsewhere for Homozygous Familial Hypercholesterolemia (HoFH) |
| Predicted New Indication | Hyperlipoproteinemia (clinically corresponds to HoFH / familial hypercholesterolemia) |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L1 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not present in this drug’s structured fields (original_moa is a data gap). However, the evidence collected under this specific prediction describes the mechanism clearly: Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor. It blocks the assembly and secretion of ApoB-containing lipoproteins (VLDL and chylomicrons) in the liver and intestine, which directly lowers LDL-cholesterol and overall plasma lipoprotein levels.
This mechanism maps directly onto hyperlipoproteinemia — particularly Homozygous Familial Hypercholesterolemia (Fredrickson type IIa), where LDL-receptor function is severely impaired and patients depend on LDL-receptor-independent pathways to lower LDL-C. Because MTP inhibition works independently of the LDL receptor, it is pharmacologically well-suited to exactly this patient population.
Importantly, the literature in this pack (e.g., PMID 23122768, the original Phase 3 registration trial, and multiple consensus/guideline documents) indicates lomitapide is already an approved therapy for HoFH internationally. This means the “predicted new indication” here largely reflects a known, established use rather than a genuinely novel repurposing signal — the TxGNN model has correctly recovered a true drug–disease relationship, but it is not new information. Whether this constitutes a “repurposing opportunity” in Canada therefore depends entirely on confirming current Canadian regulatory status, which this Evidence Pack could not establish (0 DINs, no license records).
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00690443 | Phase 2 | Completed | 44 | RCT of lomitapide (AEGR-733) + atorvastatin vs. atorvastatin monotherapy in moderate hypercholesterolemia; assessed LDL-C reduction at 4/8 weeks |
| NCT02173158 | Phase 3 | Completed | 9 | Single-arm, open-label study of lomitapide in Japanese HoFH patients on concurrent lipid-lowering therapy |
| NCT00730236 | Phase 3 | Completed | 29 | Pivotal registration trial of the MTP inhibitor AEGR-733 (lomitapide) in HoFH; long-term LDL-C and safety outcomes |
| NCT00559962 | Phase 2 | Completed | 260 | Randomized, double-blind, placebo-controlled trial of low-dose MTP inhibitor on hepatic fat accumulation (MRS-measured) |
| NCT04681170 | Phase 3 | Completed | 46 | Single-arm, multicentre study of lomitapide efficacy/long-term safety in pediatric HoFH patients on stable lipid-lowering therapy |
| NCT01556906 | Phase 2 | Completed | 6 | Open-label dose-escalation study of MTP inhibitor BMS-201038 (lomitapide) safety/tolerability in HoFH |
| NCT02765841 | Phase 3 | Withdrawn | 0 | Planned pediatric HoFH efficacy/safety study; withdrawn with no enrollment |
| NCT06832371 | N/A | Active, not recruiting | 73 | Observational study evaluating lomitapide’s effect on Major Adverse Cardiovascular Events (MACE) in HoFH |
| NCT02135705 | N/A | Recruiting | 300 | LOWER registry — global, multicentre, long-term observational registry of lomitapide safety and effectiveness |
| NCT00943306 | Phase 3 | Completed | 19 | Long-term, open-label follow-on study of continued lomitapide safety/efficacy in HoFH |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23122768 | 2013 | Phase 3 Trial | Lancet | Pivotal single-arm, open-label Phase 3 study establishing lomitapide efficacy and safety in adults with HoFH inadequately responsive to existing drugs |
| 39426393 | 2024 | Phase 3 Trial | Lancet Diabetes & Endocrinology | Efficacy-phase results (APH-19) of lomitapide in pediatric HoFH patients on standard-of-care lipid-lowering therapy |
| 37130090 | 2023 | Guideline/Consensus | European Heart Journal | 2023 EAS consensus update on HoFH diagnosis and treatment, including lomitapide’s role |
| 40494715 | 2025 | Review (real-world) | Journal of Clinical Lipidology | Over 10 years of long-term efficacy and safety data on lomitapide in HoFH |
| 39751968 | 2025 | Review | Current Atherosclerosis Reports | Review of novel pharmacological therapies, including lomitapide, for lowering LDL-C in HoFH |
| 31741187 | 2019 | Review | Current Atherosclerosis Reports | Mechanistic review of lomitapide (MTP inhibition) and mipomersen (apoB100 synthesis inhibition) |
| 21846156 | 2011 | Review | American Journal of Cardiovascular Drugs | Early drug-development review of lomitapide as an oral MTP inhibitor for familial/primary hypercholesterolemia |
| 33766264 | 2021 | Review | Journal of the American College of Cardiology | Overview of new/emerging LDL-C and ApoB-lowering therapies, including lomitapide |
| 36152419 | 2022 | Review | Atherosclerosis | Explores efficacy/safety of lomitapide in familial chylomicronaemia syndrome (indication-expansion evidence) |
| 24231894 | 2014 | Review | Journal of Cardiovascular Nursing | Review of lomitapide and mipomersen as novel lipid-lowering agents for familial hypercholesterolemia |
Canada market information is omitted — no license/DIN records exist for this drug in the dataset provided.
Safety Considerations
Please refer to the package insert for safety information.
Note: this Evidence Pack flags a Blocking-severity data gap (DG001 — TFDA/label warnings and contraindications not yet retrieved) that currently prevents any S1 safety pre-screen. This must be resolved before further evaluation, independent of the strength of the efficacy evidence above.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The efficacy evidence for lomitapide in hyperlipoproteinemia/HoFH is strong (L1: multiple completed Phase 3 studies plus a 2023 consensus guideline), but two blocking gaps prevent a full go decision: (1) no confirmed Canadian regulatory/market status (0 DINs, market status “Not Marketed”), and (2) no safety/label data (warnings, contraindications, interactions) has been retrieved. Separately, note that this indication likely represents lomitapide’s already-known/approved use rather than a genuinely new repurposing signal — the other nine TxGNN-predicted indications in this pack (rare platelet disorders) returned no supporting evidence at all and are assessed as probable model artifacts, not viable candidates.
To proceed, the following is needed:
- Retrieve TFDA/product-label warnings, contraindications, and drug-interaction data (DG001, Blocking)
- Retrieve confirmed mechanism-of-action documentation from DrugBank (DG002, High)
- Confirm current Canadian regulatory/marketing status for lomitapide (currently 0 licenses on record)
- Clarify whether “hyperlipoproteinemia” here should be treated as a repurposing candidate or as confirmation of an existing approved indication, since this materially changes the recommended decision pathway
- Do not advance the remaining nine predicted indications (thrombocytopenia/platelet disorders) without independent mechanistic justification — current evidence in this pack does not support them
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.